Sir, The increasing incidence of carbapenem-resistant Klebsiella pneumoniae is a major challenge to public health. Despite the fact that the prevalence of carbapenemases among carbapenemresistant K. pneumoniae varies geographically, the incidence of OXA-48-like enzymes has soared in recent years and is particularly high in some European countries, such as Spain and France (74% and 78% among carbapenemase-producing K. pneumoniae, respectively).
1 A significant number of OXA-48 variants have been reported in the last decade. This includes OXA-232, a carbapenemase firstly identified in France in 2011 2 and thereafter found in several countries. 3, 4 Recently, an MDR K. pneumoniae ST231 co-producing OXA-232, the ESBL CTX-M-15 and the 16S rRNA methyltransferase RmtF conferring broad-spectrum resistance to aminoglycosides has emerged as a successful epidemic clone in South-East Asia, with related outbreaks being reported in Singapore and in Brunei Darussalam between 2013 and 2015. 5, 6 Here, we report on a nosocomial spread of this emerging resistant strain in Switzerland.
Six K. pneumoniae clinical isolates with reduced susceptibility or resistant to carbapenems were recovered from February to April 2017 from five different patients, namely three hospitalized in the medicine ward of a regional hospital in Western Switzerland, and two non-hospitalized at the private Ear, Nose and Throat (ENT) centre located near to the hospital (Table 1) and were sent to the Swiss National Reference Center for Emerging Antibiotic Resistance for further characterization. All the patients reported no recent travel abroad. Clinical and epidemiological analyses failed to detect any obvious route of transmission for those isolates.
Antimicrobial susceptibility testing was performed by disc diffusion assay (Sanofi-diagnostic Pasteur, France) and MICs were determined using Etest (bioMérieux, France) and broth microdilution techniques, with susceptibility defined according to CLSI breakpoints (https://clsi.org/standards/products/microbiology/docu ments/m100/). Four isolates were resistant to penicillins, broadspectrum cephalosporins, meropenem and ertapenem and showed intermediate resistance to imipenem. The remaining two isolates displayed a typical ESBL phenotype, with resistance towards all penicillins, to expanded-spectrum cephalosporins (antagonized by b-lactamase inhibitors) and to ertapenem, and susceptibility to imipenem and meropenem. Interestingly, one isolate presenting carbapenemase activity and one exhibiting an ESBL phenotype had been recovered from a single patient (Table 1 ). All six K. pneumoniae isolates also exhibited broad-spectrum resistance to aminoglycosides and were additionally resistant to sulphonamides, fluoroquinolones, trimethoprim/sulfamethoxazole, chloramphenicol, tetracycline and to the recently developed ceftolozane/tazobactam combination. Notably, all six clinical isolates were susceptible to colistin and to the ceftazidime/avibactam combination.
Multiplex PCRs performed to detect Ambler class A, B and D carbapenemases and 16S rRNA aminoglycoside resistance genes 7, 8 followed by sequencing revealed that all six isolates possessed the rmtF 16S rRNA methyltransferase gene, and that the four carbapenem-resistant isolates possessed the bla OXA-232 carbapenemase gene. In addition, all the isolates possessed the ESBL bla CTX-M-15 and the bla TEM-1 gene ( Table 1) . Transferability of the bla OXA-232 , bla CTX-M-15 and rmtF genes was attempted by matingout assays using the azide-resistant Escherichia coli J53 as a recipient strain. Transconjugants were obtained on azide (100 mg/L) and either amikacin/gentamicin (50 mg/L each) or ceftazidime (1 mg/L), but not imipenem (1 mg/L), indicating the transferability of the plasmids harbouring the rmtF and bla CTX-M-15 , but not that one carrying the bla OXA-232 gene. Analysis of the plasmid content by using the Kieser technique revealed the presence of several plasmids in all isolates. The bla OXA-232 was carried on a 6141 bp plasmid identical to that identified by Potron et al.,
2 as further supported by sequence analysis performed as previously reported. 6 Noticeably, the rmtF and bla CTX-M-15 genes were located on the same 160 kb plasmid. PFGE of the SpeI-digested genomic DNA obtained from the six K. pneumoniae isolates revealed that they were clonally related. MLST showed that they belonged to ST231 (https://cge.cbs.dtu.dk/services/MLST/).
In an attempt to unravel the genetic factors contributing to the emergence and spread of this multiresistant pathogen, WGS of genomic DNA from isolate Kp1 (KP06-2017) was performed using a MiniSeq system (Illumina, USA), generating a total of 13 078 950 reads with an average length of 145.8 bp. Reads were de novo assembled using CLC Genomics Workbench version 7.5.1 (Qiagen, France). The draft genome revealed a size of 6 015 778 bp, with an average GC content of approximately 57%. The antimicrobial resistome was identified using ResFinder 9 and comprises genes conferring resistance to aminoglycosides (rmtF, aadB, aadA2 and aacA4), b-lactams (bla OXA-232 , bla CTX-M-15 , bla TEM-1b ), fluoroquinolones [aac(6 0 )Ib-cr], macrolides, lincosamides and streptogramin B (MLS) [erm(B) and mph(A)], phenicols (catA1 and catB4), sulphonamides (sul1), trimethoprim (dfrA12) and rifampicin (arr-2) ( Table 1) . Plasmid finder 10 revealed the presence of IncFIB(pQil), IncFII(K), IncFII(pRSB107), IncFIA and ColKP3 replicons; the latter two present in the plasmids carrying the rmtF/bla CTX-M-15 and bla OXA-232 genes, respectively.
Overall, to our knowledge, we report here the first occurrence in Europe of an MDR K. pneumoniae ST231 clone, so far geographically confined in South-East Asia. This represents an important and worrying step toward the rise of another epidemic clone as a global public threat.
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None to declare. which analysed a large series of uncommon yeast fungaemias in France. We are also concerned about the increasing incidence of these episodes, mainly reported in immunosuppressed patients, 2, 3 which could potentially change future strategies for antifungal management. Therefore, we would like to add our experience from a large tertiary hospital in Spain. We analysed all episodes in which a rare yeast was isolated from blood cultures from January 2007 to December 2016, according to recent guidelines' definitions, 4 which in summary consider rare yeast those different from Candida spp. and Cryptococcus neoformans/gattii that cause invasive infections in humans. All isolates were identified by sequencing of the ITS1-5.8S-ITS2 region. In vitro susceptibility testing was performed according to the EUCAST EDef 7.2 procedure. Given the absence of clinical breakpoints for rare yeasts, Candida albicans breakpoints were used. During this period, there were 841 episodes of yeast fungaemia in our institution including 17 isolations of rare yeasts: three of them were considered contamination of blood cultures (one Saccharomyces cerevisiae, one Rhodotorula mucilaginosa, one Magnusiomyces capitatus) and two colonizers of central venous catheters (CVCs) . As blood cultures were obtained from catheters, there were no signs of local or systemic infection and patients did not require antifungal treatment (one R. mucilaginosa, one Trichosporon asahii). Overall, 12 isolations could be considered true fungaemias (1.4% of all yeast fungaemias) caused by seven different species: R. mucilaginosa (n " 5), Trichosporon inkin (n " 2), T. asahii (n " 1), Trichosporon dermatis (n " 1), Trichosporon japonicum (n " 1), Arxula adeninivorans (n " 1) and Kodamaea ohmeri (n " 1). Incidence remained stable during the study period, with a mean of 0.02 episodes per 1000 admissions.
The main characteristics of the 12 patients are shown in Table 1 . The median age was 48 years and 66.7% of the patients were male. Overall, 8 of 12 patients (66.7%) were immunocompromised, 6 (50%) had a haematological malignancy and 6 (50%) were neutropenic. Nearly all patients (11 of 12, 91.7%) had a CVC. Most patients with trichosporonosis (4 of 5, 80%) were haematological and all of them (5 of 5, 100%) were neutropenic at the time of fungaemia.
The most common source of fungaemia was the CVC (10 of 12, 83.3%). Post-mortem necropsy detected disseminated infection in two patients with catheter-related Trichosporon fungaemia. The other presumed clinical origins were infective endocarditis and the biliary tract (one case each). Breakthrough fungaemia was observed in six patients (50%); five of them (83.3%) were receiving candins and one was receiving voriconazole (16.7%). Regarding treatment, three patients did not receive any antifungal (two died prematurely and one required catheter withdrawal only), two received an appropriate empirical antifungal and six received an appropriate targeted treatment, a mean of 6.5 days after blood culture extraction. Overall mortality was 66.7% (n " 8) and related mortality was 41.7% (n " 5).
All isolates were resistant to echinocandins. The rates of resistance to amphotericin B, fluconazole, voriconazole and posaconazole were 42%, 75%, 50% and 92%, respectively. Trichosporon isolates were mostly resistant to amphotericin B, variably susceptible to fluconazole and fully susceptible to voriconazole.
Our findings confirm that rare yeast fungaemia is still a very uncommon entity, representing only 1.4% of all our observed yeast fungaemias, which is within the 0.7%-2.8% rate 2,4,5 reported in previous series using similar definitions. Incidence remained stable over time, as reported by Bretagne et al. 1 The predominant isolation of R. mucilaginosa and Trichosporon species confirms a recent Spanish multicentre study, 6 but differs 
